Clinical Trial Update: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers [Phase 1]

View source ↗

Summary

Phase 1 study results for TTX-030 as a single agent and in combination with immunotherapy or chemotherapy in patients with advanced solid tumors and lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• TTX-030

Snippet

Sponsor: Trishula Therapeutics, Inc. | Conditions: Solid Tumor, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2025-07-02